Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab

Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab

Cadonilimab is the first bi-specific antibody approved for certain malignancies in June 2022, which has a modified Fc structure to reduce immune-related adverse events. To date, no reports have described Cadonilimab-related toxic epidermal necrolysis (TEN). Here, we report the first case of TEN-like...

Full description

Bibliographic Details
Main Authors: Peng-Yu Chen, Zi-Yun Li, Sui-Qing Cai
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Immunology
Subjects:
case report
Cadonilimab/AK104
toxic epidermal necrolysis
Adalimumab
immune-related adverse events
immune checkpoint inhibitor
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1188523/full

Similar Items

Similar Items